WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibcoâ"¢ Bactoâ"¢ CD Supreme FPM Plus and Gibcoâ"¢ Bactoâ"¢ CD Supreme Feed (2X), two next-generation chemically-defined formulations that expand the Gibcoâ"¢ Bactoâ"¢ CD portfolio to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli). As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccin. ...

Core Insights - ProteoNic BV's proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks for a project funded by BARDA, aimed at enhancing domestic biomanufacturing of monoclonal antibodies to combat filoviruses like Ebola and Sudan Virus [1][2] Group 1: Project Overview - The project has a total value of up to $22.2 million and involves a collaboration between Ginkgo Bioworks, Advanced BioScience Laboratories, Isolere Bio, NeuImmune, and ProteoNic [2] - The initiative focuses on developing innovative technologies across the entire monoclonal antibody production process, from cell line development to purification, to create a more efficient and cost-effective biomanufacturing solution [2] Group 2: ProteoNic's Role - ProteoNic's contribution centers on its 2G UNic vector and transposon technologies, which are designed to maximize expression and productivity in mammalian systems, thereby enhancing manufacturing efficiency and yield [3] - The technology aims to reduce both time and cost associated with large-scale bioproduction of monoclonal antibodies [3] Group 3: Strategic Importance - The collaboration highlights ProteoNic's expansion into next-generation biologics manufacturing, supporting therapeutic protein production and cell and gene therapy applications [4] - By improving productivity from existing manufacturing infrastructure, ProteoNic's technology aims to bolster biomanufacturing resilience against future global health threats [4]

BOSTON, Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARPA- H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D. The collaboration, Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Si ...

This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration. Partnership positions MaxYieldâ"¢ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform. ...

Core Insights - Ginkgo Bioworks has been awarded a four-year contract worth up to $47 million by the Environmental Molecular Sciences Laboratory to develop a High-Throughput Automated Phenotyping Platform [1][5] - The platform aims to enhance the U.S. Department of Energy's capabilities in generating reproducible microbial data, thereby supporting the bioeconomy and biotechnology innovation [1][4] Group 1: Contract and Collaboration - The contract is part of a competitive procurement process and will support the Microbial Molecular Phenotyping Capability [1][5] - Ginkgo Automation will utilize its Catalyst scheduling software and modular Reconfigurable Automation Carts to automate workflows from media preparation to multimodal analytics [2][3] Group 2: Technological Features - The HTPAPP is designed to support BSL2 operations, remote planning, and laboratory integration, allowing for adaptability as scientific needs evolve [2][9] - Key features include a modular architecture, integrated transport, and software-enabled interleaving of diverse protocols to maximize efficiency [2][9] Group 3: Strategic Importance - The project aligns with the recent AI Action Plan aimed at boosting U.S. scientific innovation through AI-enabled cloud laboratories [4] - The platform is expected to increase throughput and reproducibility of phenotyping campaigns, capturing multimodal analytical measurements suitable for AI and machine learning applications [5][9] Group 4: Company Overview - Ginkgo Bioworks specializes in engineering biology, offering customizable R&D solutions across various sectors including therapeutics, diagnostics, and agriculture [8] - The company also provides laboratory automation solutions to enhance research efficiency and data generation for AI models [8]

Core Viewpoint - The article emphasizes a sell rating on Ginkgo Bioworks (DNA), highlighting a significant decline in its share price over the past two years [1]. Company Summary - Ginkgo Bioworks is identified as a cell programming and biosecurity company [1]. - The company has experienced a notable decrease in its stock value, which is a central theme of the analysis [1]. Analyst Background - The author has a background in finance and accounting, with experience in investment management and portfolio management [1]. - The author has been active in the markets for several years, focusing primarily on long/short equities [1].

Financial Data and Key Metrics Changes - In Q3 2025, Ginkgo reported a cash position of $462 million with no bank debt, reflecting a significant reduction in quarterly cash burn by 75% from $114 million in Q3 2024 to $28 million in Q3 2025 [4][11] - Total adjusted EBITDA for Q3 2025 was negative $56 million, down from negative $20 million in Q3 2024, primarily due to a $21 million shortfall related to a Google Cloud contract and a $45 million non-cash revenue from a prior customer agreement [10][12] Business Line Data and Key Metrics Changes - Cell engineering revenue was $29 million in Q3 2025, a 61% decrease compared to Q3 2024, with a 5% decrease in revenue-generating programs attributed to ongoing program rationalization [6][8] - Biosecurity revenue generated $9 million in Q3 2025, with a segment gross margin of 19% [7] Market Data and Key Metrics Changes - The company reaffirmed its overall revenue guidance for 2025, projecting total revenue between $167 million and $187 million, with cell engineering revenue expected to be between $117 million and $137 million, and biosecurity revenue expected to be at least $40 million [12] Company Strategy and Development Direction - Ginkgo aims to deliver robotics and software for autonomous labs at customer sites, expand its frontier autonomous lab in Boston, and provide best-in-class CRO services leveraging in-house robotic infrastructure [2][3] - The company is focusing on AI's impact on biotechnology, particularly through reasoning models and automation, to enhance laboratory efficiency and reduce costs [13][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macro environment while continuing to execute core objectives, emphasizing the importance of investing in automation and AI tooling for future growth [12][40] - The management highlighted the need for the U.S. to invest in robotic infrastructure to compete with China's growing biotech sector [19][20] Other Important Information - Ginkgo has made significant strides in reducing costs while maintaining a strong cash position, allowing for future investments in growth [4][40] - The company is actively building a community around AI models trained on biological data through initiatives like the Antibody Developability Competition [24][26] Q&A Session Summary Question: Impact of U.S. government shutdown on Ginkgo's business - Management indicated that the shutdown has not significantly impacted the company, as grants and funding continue to flow [41] Question: Development and rollout path for the rack system - Management expressed excitement about the scalability and productization of the rack system, aiming for broader adoption in the next 18 months [42][44] Question: Ideal revenue mix by 2030 - The company envisions an 80-20 revenue mix favoring tools over services by 2030, with a focus on becoming a dominant provider of general-purpose R&D infrastructure [50][51] Question: Details on the Google Cloud contract reset - Management provided insights on favorable terms negotiated with Google, reducing future commitments and extending the contract period [52][53] Question: AI's role in R&D landscape - Management discussed the potential of AI and robotics to transform drug discovery and laboratory operations, enabling researchers to pursue multiple hypotheses simultaneously [56][58]

Grow with Ginkgo Q3 2025 Update & Business Review November 6, 2025 Property of Ginkgo Bioworks — 1 Q2 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations a ...

Revenue Generation - Ginkgo's revenue is generated primarily through cell engineering services, with a focus on license and collaboration agreements for engineered organisms [170]. - Ginkgo's cell engineering revenue includes transactions with Platform Ventures and Legacy Structured Partnerships, involving upfront non-cash consideration and R&D services [174]. - Total revenue for the nine months ended September 30, 2025, was $136.8 million, compared to $183.2 million for the same period in 2024, reflecting a decrease of $46.4 million [196]. - Cell Engineering revenue for Q3 2025 was $29.4 million, down from $75.1 million in Q3 2024, a decrease of $45.7 million, largely due to the recognition of $45.4 million in non-cash revenue from a terminated contract in Q3 2024 [197]. - Biosecurity revenue for Q3 2025 was $9.5 million, down from $14.0 million in Q3 2024, a decrease of $4.5 million, primarily due to lower revenue from U.S. government programs [201]. Expenses and Cost Management - R&D expenses decreased in the first half of 2025 compared to the first half of 2024, attributed to a restructuring plan initiated in Q2 2024 [181]. - The company expects R&D expenses to stabilize or decline in 2025, depending on technology advances and market penetration [181]. - General and Administrative (G&A) expenses were lower in the first half of 2025 compared to the first half of 2024, primarily due to a restructuring plan initiated in Q2 2024, with expectations for G&A expenses to remain consistent or decline in 2025 [183]. - Research and development expenses decreased to $69.4 million for the three months ended September 30, 2025, down from $77.0 million in 2024, a reduction of 10.0% [209]. - General and administrative expenses were $45.0 million for the three months ended September 30, 2025, down from $52.3 million in 2024, a decrease of 13.9% [211]. - The company recorded restructuring charges of $10.7 million for the nine months ended September 30, 2025, down from $20.0 million in 2024, a decrease of 46.5% [214]. Financial Performance - The net loss for Q3 2025 was $80.8 million, compared to a net loss of $56.4 million in Q3 2024, an increase in loss of $24.4 million [196]. - The company reported a net loss of $232.0 million for the nine months ended September 30, 2025, with non-cash charges of $129.1 million [233]. - Interest income, net for Q3 2025 was $5.7 million, down from $9.3 million in Q3 2024, a decrease of $3.5 million [196]. - Interest income, net for the nine months ended September 30, 2025, was $17.9 million, compared to $31.3 million in 2024, a decrease of 42.5% [217]. - Gain on investments was $3.7 million for the three months ended September 30, 2025, compared to a loss of $6.9 million in 2024 [218]. Cash Flow and Liquidity - As of September 30, 2025, the company had cash and cash equivalents and marketable securities totaling $461.9 million, expected to fund operations for at least the next 12 months [230]. - For the nine months ended September 30, 2025, net cash used in operating activities was $123.4 million, compared to $277.2 million for the same period in 2024 [232]. - Cash used in investing activities for the nine months ended September 30, 2025, was $335.4 million, primarily due to purchases of marketable debt securities totaling $401.8 million [237]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $9.6 million, mainly from an ATM offering [239]. - As of September 30, 2025, the company had cash equivalents and marketable debt securities totaling $419.6 million [242]. Strategic Initiatives - In Q3 2024, Ginkgo launched new cell engineering tools, including Datapoints and lab automation solutions, aimed at providing large biological datasets for AI model training [173]. - The Foundry and Codebase are key components of Ginkgo's platform, enhancing laboratory automation and data generation capabilities [155]. - Ginkgo's automation solutions, including Reconfigurable Automation Cart systems, enable high throughput experimentation and are expected to resolve 80-90% of system errors remotely [161]. - The company aims to build a robust early warning system for biological threats as part of its biosecurity mission [162]. - The company plans to continue R&D activities and potentially acquire companies or assets to advance its objectives [234]. Market Conditions - Inflation has not had a material effect on the company's financial condition or results of operations during the reported periods [244]. - The company anticipates expenditures will exceed revenue for at least the next 12 months [232].

Revenue Performance - Total revenue for Q3 2025 was $39 million, a decrease of 56% compared to $89 million in the same period last year, primarily due to a $45 million non-cash revenue release in the prior year[5] - Cell Engineering revenue in Q3 2025 was $29 million, down 61% from $75 million in the prior year, with a similar non-cash revenue impact[5] - Biosecurity revenue for Q3 2025 was $9 million, compared to $14 million in the same period last year[5] - Total revenue for the three months ended September 30, 2025, was $38,837,000, a decrease of 56.4% compared to $89,046,000 for the same period in 2024[19] - Cell Engineering revenue decreased to $29,380,000 in Q3 2025 from $75,089,000 in Q3 2024, representing a decline of 60.8%[27] - Biosecurity revenue for the three months ended September 30, 2025, was $9,457,000, down 32.4% from $13,957,000 in Q3 2024[27] Financial Losses - GAAP net loss for Q3 2025 was $(81) million, compared to $(56) million in the prior year[5] - The net loss for the three months ended September 30, 2025, was $80,755,000, compared to a net loss of $56,403,000 for the same period in 2024, indicating a worsening of 43.0%[19] - The company reported a basic net loss per share of $1.45 for Q3 2025, compared to a loss of $1.08 per share in Q3 2024[19] - Net loss for the nine months ended September 30, 2025, was $232,012 thousand, compared to a loss of $439,495 thousand for the same period in 2024, representing a 47% improvement[32] - The company incurred total segment operating losses of $41,616,000 for Q3 2025, compared to $11,363,000 in Q3 2024, indicating a significant increase in losses[27] Cash and Cash Equivalents - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $462 million[5] - Cash and cash equivalents at the end of the period were $111,065,000, down from $616,214,000 at the end of Q3 2024, reflecting a decrease of 82.0%[24] - Net cash used in operating activities for the nine months ended September 30, 2025, was $123,381,000, compared to $277,150,000 for the same period in 2024[23] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $128,854,000, a reduction of 10.6% compared to $144,250,000 in Q3 2024[19] - Research and development expenses for the three months ended September 30, 2025, were $69,353,000, down from $77,006,000 in Q3 2024, a decrease of 9.5%[19] Future Projections - Ginkgo expects total revenue for 2025 to be between $167 million and $187 million, with Cell Engineering revenue projected at $117 million to $137 million and Biosecurity revenue at least $40 million[11] Strategic Initiatives - Ginkgo announced a project agreement with BARDA valued at up to $22.2 million for innovations in monoclonal antibody biomanufacturing[5] - The company is expanding its frontier autonomous lab in Boston as a showcase for its capabilities[5] - Ginkgo's AI-enabled cloud lab technology is positioned to accelerate U.S. scientific innovation, aligning with the recent AI Action Plan from President Trump[3] Adjusted Financial Metrics - Adjusted EBITDA for Q3 2025 was $(56) million, down from $(20) million in the prior year[5] - Adjusted EBITDA for the nine months ended September 30, 2025, was $(131,219) thousand, an improvement from $(236,216) thousand in 2024, indicating a 44% reduction in losses[32] Other Financial Metrics - Stock-based compensation increased to $61,429 thousand for the nine months ended September 30, 2025, compared to $94,636 thousand in 2024, reflecting a 35% decrease[32] - Restructuring charges for the nine months ended September 30, 2025, totaled $10,692 thousand, down from $20,015 thousand in 2024, marking a 47% reduction[32] - Interest income, net, decreased to $(17,906) thousand for the nine months ended September 30, 2025, from $(31,275) thousand in 2024, a decline of 43%[32] - Depreciation and amortization expenses for the nine months ended September 30, 2025, were $45,327 thousand, slightly down from $47,368 thousand in 2024, a decrease of 4%[32] - The company recognized $7.5 million in non-cash revenue during the nine months ended September 30, 2025, due to the release of deferred revenue from a customer agreement[32] - Merger and acquisition-related expenses for the nine months ended September 30, 2025, were $(4,478) thousand, compared to $6,110 thousand in 2024, indicating a significant change in expenses[32] - The company reported a loss on deconsolidation of a subsidiary amounting to $7,013 thousand for the nine months ended September 30, 2024[32] - Change in fair value of convertible notes resulted in a gain of $5,685 thousand for the nine months ended September 30, 2025, compared to a gain of $1,127 thousand in 2024[32]